

In the Claims:

Cancel claims 14, 22, 30, 38, 46, 54, 62, 70, 78, and 86 without prejudice to renewal.

Replace claims 13-92 with the claims below, including amended claims 15, 21, 23, 29, 31, 37, 39, 45, 47, 53, 55, 61, 63, 69, 71, 77, 79, 85, and 87. Claims amended herein are indicated in the text in parentheses.

Add new claims 93-122.

13. (Amended) An isolated polynucleotide comprising at least 150 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:730, a degenerate variant of SEQ ID NO:730, and a complement of SEQ ID NO:730.

15. (Amended) An isolated antisense nucleic acid molecule comprising at least 150 contiguous nucleotides of the polynucleotide of claim 13.

16. An isolated recombinant host cell containing the polynucleotide of claim 13.

17. An isolated vector comprising the polynucleotide of claim 13.

18. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 13.

19. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 13 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

20. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00004158C: F03 of ATCC Deposit Number PTA-64.

21. (Amended) An isolated polynucleotide comprising at least 250 contiguous

nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:731, a degenerate variant of SEQ ID NO:731, and a complement of SEQ ID NO:731.

23. (Amended) An isolated antisense nucleic acid molecule comprising at least 250 contiguous nucleotides of the polynucleotide of claim 21.

24. An isolated recombinant host cell containing the polynucleotide of claim 21.

25. An isolated vector comprising the polynucleotide of claim 21.

26. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 21.

27. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 21 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

28. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00004031D:G02 of ATCC Deposit Number PTA-64.

29. (Amended) An isolated polynucleotide comprising at least 50 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:919, a degenerate variant of SEQ ID NO:919, and a complement of SEQ ID NO:919.

31. (Amended) An isolated antisense nucleic acid molecule comprising at least 50 contiguous nucleotides of the polynucleotide of claim 29.

32. An isolated recombinant host cell containing the polynucleotide of claim 29.

33. An isolated vector comprising the polynucleotide of claim 29.

34. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 29.

35. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 29 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

36. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00005378C:A10 of ATCC Deposit Number PTA-48.

37. (Amended) An isolated polynucleotide comprising at least 150 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:972, a degenerate variant of SEQ ID NO:972, and a complement of SEQ ID NO:972.

39. (Amended) An isolated antisense nucleic acid molecule comprising at least 150 contiguous nucleotides of the polynucleotide of claim 29.

40. An isolated recombinant host cell containing the polynucleotide of claim 29.

41. An isolated vector comprising the polynucleotide of claim 29.

42. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 29.

43. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 29 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

44. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00007118B:B04 of ATCC Deposit Number PTA-60.

45. (Amended) An isolated polynucleotide comprising at least 35 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:973, a degenerate variant of SEQ ID NO:973, and a complement of SEQ ID NO:973.

47. (Amended) An isolated antisense nucleic acid molecule comprising at least 35 contiguous nucleotides of the polynucleotide of claim 45.

48. An isolated recombinant host cell containing the polynucleotide of claim 45.

49. An isolated vector comprising the polynucleotide of claim 45.

50. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 45.

51. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 45 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

52. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00007019A:B01 of ATCC Deposit Number PTA-60.

53. (Amended) An isolated polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:1128, a degenerate variant of SEQ ID NO:1128, and a complement of SEQ ID NO:1128.

55. (Amended) An isolated antisense nucleic acid molecule comprising at least 100 contiguous nucleotides of the polynucleotide of claim 53.

56. An isolated recombinant host cell containing the polynucleotide of claim 53.
57. An isolated vector comprising the polynucleotide of claim 53.
58. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 53.
59. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 53 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.
60. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00006745A:A01 of ATCC Deposit Number PTA-53.
61. (Amended) An isolated polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:1192, a degenerate variant of SEQ ID NO:1192, and a complement of SEQ ID NO:1192.
63. (Amended) An isolated antisense nucleic acid molecule comprising at least 100 contiguous nucleotides of the polynucleotide of claim 61.
64. An isolated recombinant host cell containing the polynucleotide of claim 61.
65. An isolated vector comprising the polynucleotide of claim 61.
66. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 61.

67. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 61 under  
conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

68. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone  
deposited as clone number M00005404C:F02 of ATCC Deposit Number PTA-62.

69. (Amended) An isolated polynucleotide comprising at least 150 contiguous  
nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:1254, a  
degenerate variant of SEQ ID NO:1254, and a complement of SEQ ID NO:1254.

71. (Amended) An isolated antisense nucleic acid molecule comprising at least 150  
contiguous nucleotides of the polynucleotide of claim 69.

72. An isolated recombinant host cell containing the polynucleotide of claim 69.

73. An isolated vector comprising the polynucleotide of claim 69.

74. A library of polynucleotides, the library comprising the sequence information of the  
polynucleotide of claim 69.

75. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 69 under  
conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

76. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone  
deposited as clone number M00007163A:B10 of ATCC Deposit Number PTA-55.

77. (Amended) An isolated polynucleotide comprising at least 35 contiguous nucleotides

of a nucleotide sequence selected from the group consisting of: SEQ ID NO:1290, a degenerate variant of SEQ ID NO:1290, and a complement of SEQ ID NO:1290.

79. (Amended) An isolated antisense nucleic acid molecule comprising at least 35 contiguous nucleotides of the polynucleotide of claim 77.

80. An isolated recombinant host cell containing the polynucleotide of claim 77.

81. An isolated vector comprising the polynucleotide of claim 77.

82. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 77.

83. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 77 under conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

84. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone deposited as clone number M00022202C:F11 of ATCC Deposit Number PTA-50.

85. (Amended) An isolated polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence selected from the group consisting of: SEQ ID NO:1492, a degenerate variant of SEQ ID NO:1492, and a complement of SEQ ID NO:1492.

87. (Amended) An isolated antisense nucleic acid molecule comprising at least 100 contiguous nucleotides of the polynucleotide of claim 85.

88. An isolated recombinant host cell containing the polynucleotide of claim 85.

89. An isolated vector comprising the polynucleotide of claim 85.

90. A library of polynucleotides, the library comprising the sequence information of the polynucleotide of claim 85.

91. A method for producing a polypeptide, the method comprising the steps of:  
culturing a recombinant host cell containing the polynucleotide of claim 85 under  
conditions suitable for the expression of an encoded polypeptide;  
recovering the polypeptide from the host cell culture.

92. A polynucleotide comprising the nucleotide sequence of an insert contained in a clone  
deposited as clone number M00022404B:H05 of ATCC Deposit Number PTA-48.

Please add the following new claims.

--93. (New) An isolated polynucleotide according to claim 13, wherein the  
polynucleotide is a cDNA.

94. (New) An isolated polynucleotide according to claim 93, wherein said polynucleotide  
is expressed at a higher level in cancer cells than in normal cells.

95. (New) An isolated polynucleotide according to claim 21, wherein the polynucleotide  
is a cDNA.

96. (New) An isolated polynucleotide according to claim 95, wherein said polynucleotide  
is expressed at a higher level in cancer cells than in normal cells.

97. (New) An isolated polynucleotide according to claim 29, wherein the polynucleotide  
is a cDNA.



98. (New) An isolated polynucleotide according to claim 97, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

99. (New) An isolated polynucleotide according to claim 37, wherein the polynucleotide is a cDNA.

100. (New) An isolated polynucleotide according to claim 99, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

101. (New) An isolated polynucleotide according to claim 45, wherein the polynucleotide is a cDNA.

102. (New) An isolated polynucleotide according to claim 101, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

103. (New) An isolated polynucleotide according to claim 53, wherein the polynucleotide is a cDNA.

104. (New) An isolated polynucleotide according to claim 103, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

105. (New) An isolated polynucleotide according to claim 61, wherein the polynucleotide is a cDNA.

106. (New) An isolated polynucleotide according to claim 105, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

107. (New) An isolated polynucleotide according to claim 69, wherein the polynucleotide is a cDNA.

108. (New) An isolated polynucleotide according to claim 107, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

109. (New) An isolated polynucleotide according to claim 77, wherein the polynucleotide is a cDNA.

110. (New) An isolated polynucleotide according to claim 109, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

111. (New) An isolated polynucleotide according to claim 85, wherein the polynucleotide is a cDNA.

112. (New) An isolated polynucleotide according to claim 111, wherein said polynucleotide is expressed at a higher level in cancer cells than in normal cells.

113. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 150 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:730.

114. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 250 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:731.

115. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 50 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:919.

116. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 150 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:972.

117. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 35 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:973.

118. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:1128.

119. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:1192.

120. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 150 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:1254.

121. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 35 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:1290.

122. (New) An isolated cDNA obtained by the process of amplification using a polynucleotide comprising at least 100 contiguous nucleotides of a nucleotide sequence of SEQ ID NO:1492.--

**REMARKS UNDER 37 C.F.R. ' 1.111**

**Formal Matters**

Claims 14, 22, 30, 38, 46, 54, 62, 70, 78, and 86 are canceled.

Claims 13, 15, 21, 23, 29, 31, 37, 39, 45, 47, 53, 55, 61, 63, 69, 71, 77, 79, 85, and 87 are amended to more distinctly claim the invention. Support for these amendments is found throughout the specification, particularly on: page 4, line 34 through page 5, line 2.